Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics (NASDAQ: AKRO) is a clinical-stage biotechnology company pioneering FGF21-based therapies for metabolic diseases including NASH and MASH. This page provides investors and researchers with timely updates on clinical developments, regulatory milestones, and corporate announcements directly from the company.
Access authoritative information on Akero's lead candidate efruxifermin (EFX), including Phase 2b/3 trial progress, peer-reviewed research, and strategic partnerships. Our curated news collection covers essential updates, scientific presentations, and financial reports while maintaining strict compliance with financial disclosure standards.
Key content includes trial result analyses, FDA communications, patent developments, and executive commentary. Bookmark this page for streamlined tracking of Akero's progress in addressing liver fibrosis and metabolic dysfunction through innovative Fc-FGF21 fusion protein therapy.
Akero Therapeutics, Inc. (Nasdaq: AKRO) announced plans to discuss new efficacy and safety data from the expansion cohort of its Phase 2a clinical trial for efruxifermin (EFX), aimed at treating adults with cirrhotic non-alcoholic steatohepatitis (NASH). The update, including biopsy results, will be presented in a press release and a webcast on March 22, 2021, at 4:30 p.m. ET. Akero is focused on developing treatments for NASH, a condition without current approved therapies.
Akero Therapeutics (Nasdaq: AKRO) reported its fourth quarter and full year financial results for 2020, showcasing promising data from the Phase 2a BALANCED study on efruxifermin (EFX) for treating NASH. Notably, 50% of patients with baseline fibrosis F2 or F3 showed a two-stage improvement in fibrosis after 16 weeks. The company holds $268.4 million in cash and equivalents at year-end. R&D expenses rose to $64.9 million, reflecting investment in EFX clinical trials. Akero plans to present more data by April 2021 and expects to complete enrollment in the Phase 2b HARMONY study this year.
Akero Therapeutics (Nasdaq: AKRO) announced its participation in two upcoming virtual investor conferences in March 2021. The Cowen 41st Annual Healthcare Conference is scheduled for March 2, while the 2021 H.C. Wainwright Global Life Sciences Conference will take place on March 9. The company will offer live webcasts of its presentations, which will be accessible through their investor relations website. Akero is focused on developing therapies for non-alcoholic steatohepatitis (NASH), with its lead program, EFX, currently in Phase 2 clinical trials.
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology firm, has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2021, at 10:50 a.m. EST. Investors can view the live webcast through the company's website, with an archived version available for 30 days post-event.
Akero is focused on developing innovative treatments for non-alcoholic steatohepatitis (NASH) and metabolic disorders. Its lead drug candidate, Efruxifermin (EFX), is undergoing a Phase 2a clinical trial.
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company focused on treatments for non-alcoholic steatohepatitis (NASH) and metabolic disorders, will present at Evercore’s 3rd Annual HealthCONx virtual conference. The fireside chat is scheduled for 11:20 a.m. ET on December 3, 2020. A live webcast and a replay will be accessible on the company's investor relations website for 30 days post-event. Akero's lead candidate, Efruxifermin (formerly AKR-001), is currently in a Phase 2a clinical trial, aiming to combat the NASH epidemic.
Akero Therapeutics (Nasdaq: AKRO) presented new data from its Phase 2a BALANCED study at The Liver Meeting®, highlighting efruxifermin (EFX) as a promising monotherapy for non-alcoholic steatohepatitis (NASH). The study revealed significant reductions in liver fat, with 100% of patients in the 50mg EFX group achieving over 50% relative reduction. Additionally, 50% of patients with fibrosis stage F2 or F3 experienced a two-stage improvement. EFX, showing positive effects on glycemic control, is expected to enter a Phase 2b/3 trial in 2021, supported by EMA’s PRIME designation.
Akero Therapeutics (Nasdaq: AKRO) reported its Q3 2020 financial results, highlighting significant advancements in its NASH treatment, efruxifermin (EFX).
The company raised over $216 million through an equity offering and received FDA feedback facilitating an adaptive Phase 2b/3 clinical trial. EFX also gained PRIME designation from EMA, underscoring its potential in the NASH market.
Cash reserves stood at $291.9 million as of September 30, 2020, while operating expenses increased to $21.5 million for Q3 due to higher research and development costs.
Akero Therapeutics (Nasdaq: AKRO), a biotechnology company focused on treatments for non-alcoholic steatohepatitis (NASH), will present at two investor conferences in November 2020. The 29th Annual Credit Suisse Healthcare Conference is scheduled for November 9 at 1:15 PM EST, and the Jefferies Global Healthcare Conference on November 17 at 1:45 PM EST. Live webcasts will be available on their website, with archived replays following the presentations. Akero is dedicated to reversing the NASH epidemic through innovative medicines, particularly their lead candidate, efruxifermin.
Akero Therapeutics (Nasdaq: AKRO) announced that the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to efruxifermin (EFX), an investigational treatment for non-alcoholic steatohepatitis (NASH). This designation follows promising results from the Phase 2a BALANCED study, where 48% of patients showed significant improvement. The PRIME program aims to expedite the development of EFX as it addresses unmet medical needs in NASH, which affects millions globally.
Akero Therapeutics (Nasdaq: AKRO) announced that an abstract detailing analyses from the Phase 2a BALANCED study of efruxifermin (EFX) has been accepted for presentation at The Liver Meeting Digital Experience 2020, scheduled for November 13-16. The presentation will highlight significant reductions in liver fat and ALT levels among NASH patients after 16 weeks of EFX treatment. NASH affects around 17 million Americans, highlighting the potential market need and impact of EFX in treating this condition. The next Phase 2b/3 pivotal study is set to begin in early 2021.
FAQ
What is the current stock price of Akero Therapeutics (AKRO)?
What is the market cap of Akero Therapeutics (AKRO)?
